|
|
|
You can get e-magazine links on WhatsApp. Click here
|
|
|
|
|
|
Tate & Lyle research uncovers shifting eating habits in the GLP-1 era
|
|
Monday, 24 November, 2025, 16 : 00 PM [IST]
|
|
Chicago, USA
|
Tate & Lyle has published new consumer research revealing how GLP-1 medications are dramatically reshaping eating behaviours — and what this means for the food and beverage industry.
The proprietary study, conducted in May 2025, surveyed 500 current and former GLP-1 users across North America to understand their evolving preferences, unmet needs, and long-term consumption trends.
According to Tate & Lyle, the findings indicate that GLP-1 usage isn’t a passing fad, but a transformational shift in how people eat — with deep implications for product developers. Among current users, there is a strong desire for “food joy”: smaller, nutrient-dense portions that remain indulgent and comforting through rich textures.
Former users, on the other hand, face a resurgence of appetite and “food noise” once the medication is stopped. For them, Tate & Lyle suggests that fibre-rich and protein-fortified formulations may help sustain weight-management habits.
Taste, texture, and satiety are emerging as critical drivers for this group. The research found that satisfying mouthfeel — especially layered textures combining crispy, creamy, and airy sensations — encourages slower eating, which in turn promotes fullness.
Timing also matters. The study showed that early-stage GLP-1 users are 2.5 times more open to adopting healthier, texture-forward products compared to those further along the GLP-1 journey.
Tate & Lyle sees two major innovation opportunities from these insights. First, helping former users manage renewed hunger. Second, designing “permissible indulgence” — snacks or meals that balance pleasure and nutrition using smart ingredient and texture design.
Emma Cahill, Platform Marketing Director for Sweeteners & Fibre at Tate & Lyle, said the company is well-placed to support such innovation. “With our portfolio of sweeteners, fibres, and plant-based texturants, we can help manufacturers create products that are both healthy and delicious,” she explained.
As GLP-1 medications continue to influence eating behaviour, Tate & Lyle’s research offers a roadmap for brands to deliver satisfying, science-backed products for a rapidly changing consumer segment.
|
|
|
|
|
|
|
|
|
|